A clinical trial patient plops onto a sofa, slips on shades and receives a psychedelic drug as soft music plays in the background.  As our neuronaut soon spirals through the astral plane, what could possibly go wrong?

Plenty, it turns out—from heart complications to intense perceptual disturbances. The U.S. Food and Drug Administration late last month provided the health care industry welcome guidance that could mitigate legal risks as researchers increasingly explore psychedelics for use in prescription drugs and therapies.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]